These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 34632510)

  • 1. The Role of Estrone in Feminizing Hormone Treatment.
    Tebbens M; Heijboer AC; T'Sjoen G; Bisschop PH; den Heijer M
    J Clin Endocrinol Metab; 2022 Jan; 107(2):e458-e466. PubMed ID: 34632510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sublingual Estradiol Is Associated with Higher Estrone Concentrations than Transdermal or Injectable Preparations in Transgender Women and Gender Nonbinary Adults.
    Cirrincione LR; Winston McPherson G; Rongitsch J; Sadilkova K; Drees JC; Krasowski MD; Dickerson JA; Greene DN
    LGBT Health; 2021; 8(2):125-132. PubMed ID: 33439749
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of gender affirming hormone treatment in transgender individuals - a retrospective cohort study.
    Muir CA; Guttman-Jones M; Man EJ
    Endocrine; 2024 Jul; 85(1):370-379. PubMed ID: 38386168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gender-affirming hormone treatment modalities for transfemale & non-binary transfeminine individuals: A UK perspective.
    Sagar RC; Millson-Brown V
    Best Pract Res Clin Endocrinol Metab; 2024 Sep; 38(5):101921. PubMed ID: 39232976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hormonal Management for Transfeminine Individuals.
    Abramowitz J; Tangpricha V
    Clin Plast Surg; 2018 Jul; 45(3):313-317. PubMed ID: 29908618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MANAGEMENT OF ENDOCRINE DISEASE: Optimal feminizing hormone treatment in transgender people.
    Glintborg D; T'Sjoen G; Ravn P; Andersen MS
    Eur J Endocrinol; 2021 Jun; 185(2):R49-R63. PubMed ID: 34081614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toward a Lowest Effective Dose of Cyproterone Acetate in Trans Women: Results From the ENIGI Study.
    Kuijpers SME; Wiepjes CM; Conemans EB; Fisher AD; T'Sjoen G; den Heijer M
    J Clin Endocrinol Metab; 2021 Sep; 106(10):e3936-e3945. PubMed ID: 34125226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erythrocytosis in a Large Cohort of Trans Men Using Testosterone: A Long-Term Follow-Up Study on Prevalence, Determinants, and Exposure Years.
    Madsen MC; van Dijk D; Wiepjes CM; Conemans EB; Thijs A; den Heijer M
    J Clin Endocrinol Metab; 2021 May; 106(6):1710-1717. PubMed ID: 33599731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and rapid efficacy of guideline-based gender-affirming hormone therapy: an analysis of 388 individuals diagnosed with gender dysphoria.
    Meyer G; Mayer M; Mondorf A; Flügel AK; Herrmann E; Bojunga J
    Eur J Endocrinol; 2020 Feb; 182(2):149-156. PubMed ID: 31751300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progesterone Is Important for Transgender Women's Therapy-Applying Evidence for the Benefits of Progesterone in Ciswomen.
    Prior JC
    J Clin Endocrinol Metab; 2019 Apr; 104(4):1181-1186. PubMed ID: 30608551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicians in the Veterans Health Administration initiate gender-affirming hormone therapy in concordance with clinical guideline recommendations.
    Jasuja GK; Wolfe HL; Reisman JI; Vimalananda VG; Rao SR; Blosnich JR; Livingston NA; Shipherd JC
    Front Endocrinol (Lausanne); 2024; 15():1086158. PubMed ID: 38800485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Approach to the Patient: Pharmacological Management of Trans and Gender-Diverse Adolescents.
    O'Connell MA; Nguyen TP; Ahler A; Skinner SR; Pang KC
    J Clin Endocrinol Metab; 2022 Jan; 107(1):241-257. PubMed ID: 34476487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained Breast Development and Breast Anthropometric Changes in 3 Years of Gender-Affirming Hormone Treatment.
    de Blok CJM; Dijkman BAM; Wiepjes CM; Staphorsius AS; Timmermans FW; Smit JM; Dreijerink KMA; den Heijer M
    J Clin Endocrinol Metab; 2021 Jan; 106(2):e782-e790. PubMed ID: 33206172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gender-affirming hormone therapy for transgender and gender-diverse adults in Australia.
    Nolan BJ; Cheung AS
    Intern Med J; 2024 Sep; 54(9):1450-1457. PubMed ID: 39056542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Gender-Affirming Hormone Therapy on Insulin Sensitivity and Incretin Responses in Transgender People.
    Shadid S; Abosi-Appeadu K; De Maertelaere AS; Defreyne J; Veldeman L; Holst JJ; Lapauw B; Vilsbøll T; T'Sjoen G
    Diabetes Care; 2020 Feb; 43(2):411-417. PubMed ID: 31740479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feminizing Hormone Therapy Prescription Patterns and Cardiovascular Risk Factors in Aging Transgender Individuals in Australia.
    Balcerek MI; Nolan BJ; Brownhill A; Wong P; Locke P; Zajac JD; Cheung AS
    Front Endocrinol (Lausanne); 2021; 12():667403. PubMed ID: 34326812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different hepatobiliary effects of oral and transdermal estradiol in postmenopausal women.
    Van Erpecum KJ; Van Berge Henegouwen GP; Verschoor L; Stoelwinder B; Willekens FL
    Gastroenterology; 1991 Feb; 100(2):482-8. PubMed ID: 1898652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addition of progesterone to feminizing gender-affirming hormone therapy in transgender individuals for breast development: a randomized controlled trial.
    Dijkman BAM; Helder D; Boogers LS; Gieles NC; van Heesewijk JO; Slaa ST; Liberton NPTJ; Wiepjes CM; de Blok CJM; den Heijer M; Dreijerink KMA
    BMC Pharmacol Toxicol; 2023 Dec; 24(1):80. PubMed ID: 38124194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Midwifery Care for Transfeminine Individuals.
    Ellis SA; Dalke L
    J Midwifery Womens Health; 2019 May; 64(3):298-311. PubMed ID: 30957961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of estrone on thrombin generation may explain the different thrombotic risk between oral and transdermal hormone replacement therapy.
    Bagot CN; Marsh MS; Whitehead M; Sherwood R; Roberts L; Patel RK; Arya R
    J Thromb Haemost; 2010 Aug; 8(8):1736-44. PubMed ID: 20553380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.